Tonix Pharmaceuticals (NASDAQ: TNXP) announced a research collaboration with Makana Therapeutics to evaluate TNX-1500, its anti-CD40L monoclonal anti ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 10.75%, which has investors questioning if this is right ...

Tonix Pharmaceuticals (TNXP) announced a collaborative research agreement under which Tonix and Makana will study Tonix’s anti-CD40L monoclonal ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company, presented data at the AAPM 2025 Annual Meeting showing that its ...

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the AAPM 2025 Annual Meeting, held April 3-6, 2025, in Austin, Texas.

TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

This significant rise was driven by a positive regulatory update for TNX-102 SL, the company's leading drug candidate. The FDA announced it would not require an advisory committee meeting to ...